Cargando…
Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis
AIM: It has been reported that more than half of breast cancer (BC) could be identified as HER2-low-positive, which might be a distinct subtype. But the results are controversial. We aim to compare the survival outcomes between HER2-low-positive and HER2-0 BC with Asian women based on HR status or K...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489376/ https://www.ncbi.nlm.nih.gov/pubmed/36147446 http://dx.doi.org/10.1155/2022/4364151 |
_version_ | 1784792865213251584 |
---|---|
author | Qi, Wei-Xiang Chen, Lingyan Cao, Lu Xu, Cheng Cai, Gang Chen, Jiayi |
author_facet | Qi, Wei-Xiang Chen, Lingyan Cao, Lu Xu, Cheng Cai, Gang Chen, Jiayi |
author_sort | Qi, Wei-Xiang |
collection | PubMed |
description | AIM: It has been reported that more than half of breast cancer (BC) could be identified as HER2-low-positive, which might be a distinct subtype. But the results are controversial. We aim to compare the survival outcomes between HER2-low-positive and HER2-0 BC with Asian women based on HR status or Ki-67 index. METHODS: Between January 2009 and December 2017, HER2-nonamplified BC in our single institute was identified. Patients were classified as HER2-low and HER2-0 cohort. Clinical characteristics were compared between these two groups and survival outcomes were calculated by the Kaplan–Meier method. We also performed subgroup analysis according to Ki-67 index and hormone-receptor (HR) status. RESULTS: Of the 2,230 included patients, 536 presented with HER2-0, and 1,694 with HER2-low positive. After a median follow-up of 85 months (range: 1–152 months), the 8-year OS, BCSS, and RFS of the overall cohort were 91%, 95%, and 89%, respectively. In comparison with the HER2-0 cohort, majority of HER2-low-expression BC concurrently presented with HR positive (82.3% vs. 69%, P < 0.001). There was no significant survival difference between the two groups in terms of OS, BCSS, and RFS (all p > 0.05). We then performed subgroup analysis according to HR status and Ki-67 index (<14% vs. ≥14%). Our results indicated that there was no significant survival difference between HER2-low-positive and HER2-0 tumors regardless of HR status (p > 0.05), while OS (p=0.026) and BCSS (p=0.052) of HER2-0 BC with high Ki-67 index were significantly poorer than that of HER2-low positive with high Ki-67, but not for RFS (p=0.17). CONCLUSION: Among early stage HER2-nonamplified BC, no significant survival difference could be found between HER2-low positive and HER2-0 cohort regardless of HR status. Survival outcomes of HER2-low positive with high Ki-67 seem to be poorer than that of HER2-0 tumors with high Ki-67 index. |
format | Online Article Text |
id | pubmed-9489376 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-94893762022-09-21 Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis Qi, Wei-Xiang Chen, Lingyan Cao, Lu Xu, Cheng Cai, Gang Chen, Jiayi J Oncol Research Article AIM: It has been reported that more than half of breast cancer (BC) could be identified as HER2-low-positive, which might be a distinct subtype. But the results are controversial. We aim to compare the survival outcomes between HER2-low-positive and HER2-0 BC with Asian women based on HR status or Ki-67 index. METHODS: Between January 2009 and December 2017, HER2-nonamplified BC in our single institute was identified. Patients were classified as HER2-low and HER2-0 cohort. Clinical characteristics were compared between these two groups and survival outcomes were calculated by the Kaplan–Meier method. We also performed subgroup analysis according to Ki-67 index and hormone-receptor (HR) status. RESULTS: Of the 2,230 included patients, 536 presented with HER2-0, and 1,694 with HER2-low positive. After a median follow-up of 85 months (range: 1–152 months), the 8-year OS, BCSS, and RFS of the overall cohort were 91%, 95%, and 89%, respectively. In comparison with the HER2-0 cohort, majority of HER2-low-expression BC concurrently presented with HR positive (82.3% vs. 69%, P < 0.001). There was no significant survival difference between the two groups in terms of OS, BCSS, and RFS (all p > 0.05). We then performed subgroup analysis according to HR status and Ki-67 index (<14% vs. ≥14%). Our results indicated that there was no significant survival difference between HER2-low-positive and HER2-0 tumors regardless of HR status (p > 0.05), while OS (p=0.026) and BCSS (p=0.052) of HER2-0 BC with high Ki-67 index were significantly poorer than that of HER2-low positive with high Ki-67, but not for RFS (p=0.17). CONCLUSION: Among early stage HER2-nonamplified BC, no significant survival difference could be found between HER2-low positive and HER2-0 cohort regardless of HR status. Survival outcomes of HER2-low positive with high Ki-67 seem to be poorer than that of HER2-0 tumors with high Ki-67 index. Hindawi 2022-09-13 /pmc/articles/PMC9489376/ /pubmed/36147446 http://dx.doi.org/10.1155/2022/4364151 Text en Copyright © 2022 Wei-Xiang Qi et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Qi, Wei-Xiang Chen, Lingyan Cao, Lu Xu, Cheng Cai, Gang Chen, Jiayi Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis |
title | Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis |
title_full | Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis |
title_fullStr | Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis |
title_full_unstemmed | Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis |
title_short | Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis |
title_sort | ki-67 index provides long-term survival information for early-stage her2-low-positive breast cancer: a single-institute retrospective analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489376/ https://www.ncbi.nlm.nih.gov/pubmed/36147446 http://dx.doi.org/10.1155/2022/4364151 |
work_keys_str_mv | AT qiweixiang ki67indexprovideslongtermsurvivalinformationforearlystageher2lowpositivebreastcancerasingleinstituteretrospectiveanalysis AT chenlingyan ki67indexprovideslongtermsurvivalinformationforearlystageher2lowpositivebreastcancerasingleinstituteretrospectiveanalysis AT caolu ki67indexprovideslongtermsurvivalinformationforearlystageher2lowpositivebreastcancerasingleinstituteretrospectiveanalysis AT xucheng ki67indexprovideslongtermsurvivalinformationforearlystageher2lowpositivebreastcancerasingleinstituteretrospectiveanalysis AT caigang ki67indexprovideslongtermsurvivalinformationforearlystageher2lowpositivebreastcancerasingleinstituteretrospectiveanalysis AT chenjiayi ki67indexprovideslongtermsurvivalinformationforearlystageher2lowpositivebreastcancerasingleinstituteretrospectiveanalysis |